

# Optimal and worst examination strategies for COVID-19

Onishi Tatsuki<sup>a,b</sup>, Honda Naoki<sup>c,d,e,†</sup>, Yasunobu Igarashi<sup>f,g,\*</sup>

<sup>a</sup> Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshidakonoecho, Sakyo, Kyoto, Japan

<sup>b</sup> Department of Anaesthesiology, Tokyo Metropolitan Bokutoh Hospital, Kotobashi, Sumida, Tokyo, Japan

<sup>c</sup> Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University, Higashihiroshima, Hiroshima, Japan

<sup>d</sup> Theoretical Biology Research Group, Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, Okazaki, Aichi, Japan

<sup>e</sup> Laboratory of Theoretical Biology, Graduate School of Biostudies, Kyoto University, Yoshidakonoecho, Sakyo, Kyoto, 606-8315, Japan

<sup>f</sup> E2D3.org, izumi-cho, Kokubunji, Tokyo, Japan

<sup>g</sup> Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of Technology, Nagoya, Aichi, Japan

\* Corresponding author

Yasunobu Igarashi

Center for Research on Assistive Technology for Building a New Community, Nagoya Institute of Technology

Gokiso-cho, Showa-ku, Nagoya, Aichi, 466-8555 Japan

Tel.: +81-52-735-5334

E-mail: [yasunobu.igarashi@gmail.com](mailto:yasunobu.igarashi@gmail.com)

† Co-corresponding author

Honda Naoki

Laboratory for Data-driven Biology, Graduate School of Integrated Sciences for Life, Hiroshima University, 1-3-2 Kagamiyama, Higashi-Hiroshima City, Hiroshima, 739-8511 Japan

Tel.: +81-82-424-7336

E-mail: [nhonda@hiroshima-u.ac.jp](mailto:nhonda@hiroshima-u.ac.jp)

34 **Abstract**

35 Coronavirus disease 2019 (COVID-19) is an emerging threat to the whole world, and every government is  
36 seeking an optimal solution. However, none of them have succeeded, and they have only provided series of  
37 natural experiments. Although simulation studies seem to be helpful, there is no model that addresses the  
38 how much testing to be conducted to minimise the emerging infectious disease outbreaks. In this study, we  
39 develop a testing susceptible, infectious, exposed, recovered, and dead (testing-SEIRD) model using two  
40 discrete populations inside and outside hospitals. The populations that tested positive were isolated. Through  
41 the simulations, we examined the infectious spread represented by the number of cumulative deaths,  
42 hospitalisations, and positive tests, depending on examination strategies, testing characteristics, and  
43 hospitalisation capacity. We found all-or-none responses of either expansion or extinction of the infectious  
44 spreads, depending on the rates of follow-up and mass testing, which represent testing the people identified  
45 as close contacts with infected patients using follow-up surveys and people with symptoms, respectively. We  
46 also demonstrated that there were optimal and worst examination strategies, which were determined by the  
47 total resources and testing costs. The testing-SEIRD model is useful in making decisions on examination  
48 strategies for the emerging infectious disease outbreaks.

49

## 50 1. Introduction

51 Coronavirus disease 2019 (COVID-19) emerged in Wuhan, China. It has already spread worldwide [1,2]. So  
52 far, 5.5 million people have been infected, and 350,000 people have died [3]. Owing to its high transmission  
53 ability via aerosol, COVID-19 is an emerging concern in global health care. This is similar to influenza,  
54 which annually leads to 300,000 to 600,000 deaths worldwide [4]. In addition, the fatality rate of COVID-19  
55 is 3% – 4%, which is relatively higher than 1% for influenza [5], owing to lack of a specific radical treatment  
56 or vaccine. Even worse, the infectious period of COVID-19 is 20 days longer than the three days for  
57 influenza [6], and COVID-19 causes multiple secondary infections. Therefore, testing for COVID-19 is  
58 important for the early detection of asymptomatic infected people and prevention of secondary infections.  
59 However, the effect of testing policy on the spread or reduction of COVID-19 infection dynamics remains  
60 elusive.

61 Currently, there is a social problem because medical resources in hospitals are largely consumed by  
62 treatments for COVID-19 patients. Symptomatic treatments for patients with pneumonia require both beds  
63 and healthcare providers; however, there are limited equipment such as intensive care units, ventilators,  
64 haemodialysis, and extracorporeal membrane oxygenators. If symptoms develop, intensive care units are  
65 necessary. Consequently, hospital stay for COVID-19 has become exceedingly long, indicating a median of  
66 29 days [7–11]. The imbalance between the supply and demand of medical resources causes the increase in  
67 the number of deaths after infection [11,12]. Therefore, each country must control the balance between the  
68 medical supply and demand from people who visit hospitals and need testing for COVID-19.

69 There is a controversy between two extreme policies to balance the medical supply and demand:  
70 “mass testing policy” and “no testing policy” [13]. The mass testing policy claims that all people must be  
71 tested for public health, regardless of the symptoms. As the director of WHO, Tedros said, “test, test, test” in  
72 an opening remark on 16 March 2020 [14]. The WHO and some researchers follow the mass testing policy  
73 [15,16]. This policy is based on the assumption that the testing accuracy is sufficiently high, and when more  
74 testing is conducted, the total number of deaths is reduced. Contrary to the mass testing policy, no testing  
75 policy claims that testing must be limited to people with symptoms. This indicates that it does not  
76 recommend testing for people with asymptomatic or mild symptoms or having no contact with infectious  
77 people. This policy underlies the idea that individuals are unable to expect a benefit from mass testing in the  
78 absence of the specific treatment. This was expressed by the committee for the emerging and re-emerging  
79 infectious disease in the Japanese society of paediatrics on 13th March 2020 [17]. Although there is  
80 discordance in these two policies with different beliefs, these two policies agree with testing on people with  
81 symptoms. They also disagree on the extent of the population tested.

82 Essentially, society demands the minimisation of the number of deaths [18]. Thus, we need to  
83 explore the most practical policy by integrating these extreme policies. Consequently, we must notice the  
84 advantages and disadvantages of testing. The proof of testing is simply that it can detect infected  
85 asymptomatic people. Thus, testing is helpful to save lives before developing severe symptoms and can  
86 prevent further spread of the infection. The reason for testing is that testing itself is not perfect, and it is

87 inevitable from false positives and negatives. If uninfected people are evaluated as positive by testing (i.e.,  
88 false positives are hospitalised), the people are subject to the risk of high infection from infected patients in  
89 the hospital.

90 The examination has two strategies: follow-up testing-dominant strategies which follow the exposed  
91 population and mass testing-dominant strategy which considers the infected population by random testing.  
92 However, the extent to which the follow-up and mass testing should be conducted to minimise deaths,  
93 hospitalisations, and positive tests is yet to be considered. Therefore, we need to predict the infection  
94 dynamics affected by the examination strategies, or the rate of follow-up and mass testing. We also noticed  
95 that the effect of testing on the overall infection population dynamics has not been adequately considered.  
96 Therefore, we need to predict the infection dynamics affected by the amount of testing by considering the  
97 testing characteristics (i.e., sensitivity and specificity) to quantify their positive and negative impacts.

98 In this study, we develop a testing-SEIRD model by introducing a hospitalised subpopulation,  
99 examination strategy, and testing characteristics. Through simulations, we examined the impact of the  
100 examination strategies and testing characteristics on the balance between medical supply and demand. We  
101 found that there are optimal and worst strategies and highlighted which examination strategy is preferred,  
102 based on the testing characteristics.

103

## 104 2. Model

105 To examine the effect of testing on the infection population dynamics, we developed a new model by  
 106 introducing a hospitalised subpopulation, examination strategy, and testing characteristics into the classical  
 107 SEIRD model. In general, the SEIRD model is described by the subpopulation dynamics of susceptible,  
 108 exposed, infectious, recovered, and dead people (Fig. 1A) as:

$$\frac{dS}{dt} = -\frac{bIS}{N}, \#(2.1)$$

$$\frac{dE}{dt} = \frac{bIS}{N} - gE, \#(2.2)$$

$$\frac{dI}{dt} = gE - (r + d)I, \#(2.3)$$

$$\frac{dR}{dt} = rI, \#(2.4)$$

$$\frac{dD}{dt} = dI, \#(2.5),$$

109 where  $S$ ,  $E$ ,  $I$ ,  $R$ , and  $D$  indicate the populations of susceptible, exposed, infectious, recovered, and dead  
 110 people, respectively.  $N$  indicates the total population, that is,  $N=S+E+I+R$ .  $b$  indicates the exposure rate,  
 111 which reflects the level of social activity;  $g$ ,  $r$ , and  $d$  indicate the transition rates among the subpopulations.  
 112 For this model, it is assumed that the recovered populations acquire permanent immunity, indicating that  
 113 they will never be infected.

114 Regarding the testing-SEIRD model, we incorporated the testing characteristics and examination  
 115 strategy into the classical SEIRD model by dividing the population into outside and inside of the hospitals  
 116 (Fig. 1B). The dynamics of the population outside the hospitals are described by:

$$\frac{dS_o}{dt} = -\frac{bI_o S_o}{N_o} + uE_o - aS_h, \#(2.6)$$

$$\frac{dE_o}{dt} = \frac{bI_o S_o}{N_o} - (u + g)E_o - f(1 - Sp)E_o H(C - N_h), \#(2.7)$$

$$\frac{dI_o}{dt} = gE_o - (r_o + d_o)I_o - mSeI_o H(C - N_h), \#(2.8)$$

$$\frac{dR_o}{dt} = r_o I_o, \#(2.9)$$

$$\frac{dD_o}{dt} = d_o I_o, \#(2.10),$$

117 and those inside hospitals were described by:

$$\frac{dS_h}{dt} = -\frac{bI_h S_h}{N_h} + uE_h + aS_h, \#(2.11)$$

$$\frac{dE_h}{dt} = \frac{bI_h S_h}{N_h} - (u + g)E_h + f(1 - Sp)E_o H(C - N_h), \#(2.12)$$

$$\frac{dI_h}{dt} = gE_h - (r_h + d_h)I_h + mSeI_o H(C - N_h), \#(2.13)$$

$$\frac{dR_h}{dt} = r_h I_h, \#(2.14)$$

$$\frac{dD_h}{dt} = d_h I_h, \#(2.15).$$

118  $X_o$  and  $X_h$  indicate each population outside and inside the hospitals ( $X \in \{S, E, I, R, D, N\}$ ).  $N_o$  and  $N_h$   
 119 indicate the total populations outside and inside hospitals, respectively (i.e.,  $N_o = S_o + E_o + I_o + R_o + D_o$  and  
 120  $N_h = S_h + E_h + I_h$ );  $a$  indicates the rate of discharge of  $S_h$  from hospital to the outside;  $u$  and  $g$  indicate the non-  
 121 infection and infection rates, respectively; and  $C$  indicates the capacity of hospitals. We assumed that these  
 122 parameters are determined by the nature of the disease; thus, they are independent of inside and outside  
 123 hospitals.  $r_j$  and  $d_j$  ( $j \in \{o, h\}$ ) indicate the recovery and death rates from infected, respectively, where  $r_o < r_h$ ,  
 124 and  $d_h < d_o$ .  $f$  and  $m$  indicate the rates of follow-up and mass testing, corresponding to the extent to which  
 125 health centres follow exposed populations and take-up infected populations having symptoms, respectively.  
 126  $Sp$  and  $Se$  indicate specificity and sensitivity, respectively, as testing characteristics. Mass testing in this  
 127 model is a mass test for individuals who claim symptoms. This model is a generalised version of the classic  
 128 SEIRD model. If  $u=0$ , our model is equivalent to the classical SEIRD model. The hospitalisation capacity  
 129 was introduced by the sigmoid function  $H(x) = 1/(1+\exp(x))$ . The parameter values and initial conditions are  
 130 listed in Table 1 and discussed in the Materials and Methods section.

131

### 132 3. Results

133 We first examine the basic behaviour of the testing-SEIRD model by simulation as shown in Fig. 2. Similar  
134 to the classical SEIRD model, infection largely expanded, and the infectious population ( $I_h$  and  $I_o$ ) transiently  
135 increased in response to the occurrence of infectious people. Susceptible populations ( $S_h$  and  $S_o$ ) gradually  
136 decreased and shifted into recovered populations ( $R_h$  and  $R_o$ ) through the exposed ( $E_h$  and  $E_o$ ) and infectious  
137 ( $I_h$  and  $I_o$ ) states. During this process, the number of dead cells increases gradually as shown in Fig. 2A. The  
138 hospitalised population increase, plateau at the capacity of hospitalisations within the period of infection  
139 overshoot, and decrease by the hospital discharge (Fig. 2B). The outside population decrease by  
140 hospitalisations through testing and switch to a constant decrease, whereas the hospitalised population  
141 reaches its capacity and increases by the hospital discharge (Fig. 2B). Moreover, the outside and hospitalised  
142 populations are divided into five types of populations (susceptible, exposed, infectious, recovered, and dead)  
143 (Fig. 2C and D). Daily reports of positive tests and deaths transiently increase with different peak timings,  
144 and the peak of positive tests precedes that of deaths (Fig. 2E). Reproduction numbers (see Materials and  
145 Methods) outside hospitals  $RN_o$  switch from greater than one to less than one around the peak timing of  
146 infectious populations outside (Fig. 2F). On the contrary, reproduction numbers inside hospitals  $RN_h$  are less  
147 than one. This indicates that the infectious population in hospitals increases owing to supply from the  
148 outside; however, it is not because of the infectious spread in hospitals. The testing-SEIRD model  
149 recapitulates basic infection dynamics of the total population as observed in the classical SEIRD model (Fig.  
150 2A), and enables us to examine the effect of the examination strategy and testing characteristics with  
151 different populations inside and outside hospitals.

152 To investigate the impact of hospitalisation capacity on infection dynamics, such as daily reports of  
153 positive tests, hospitalisations, and deaths, we simulate the testing-SEIRD model with various capacities (Fig.  
154 3A to C). We observe that as the capacity increases, the maximum positive tests, maximum hospitalisations,  
155 and cumulative deaths linearly decrease, increase, and decrease, respectively, and they all plateau at  
156 approximately 30% capacity (Fig. 3D to F). We have also examined their peak timings and have observe that  
157 they change nonlinearly, with certain time window ranges (Fig. 3G–I). These results suggest that the change  
158 in capacity has a large effect on the level of spread of the disease; nonetheless, it has a small effect on timing.

159 To illustrate the impact of the examination strategy on infectious outcomes, we examined the  
160 cumulative deaths, maximum number of positive tests and hospitalisations, varying follow-up and mass  
161 testing rates. The infectious spread shows an all-or-none response depending on the testing strategy (red and  
162 blue regions in Fig. 4). Sensitivity analyses confirmed that such a profile was robustly maintained  
163 independent of the model parameters (Fig. S1 and S2).

164 The number of cumulative deaths is almost constant with a small amount of both the follow-up and  
165 mass testing (red region in upper panel of Fig. 4A); nonetheless, the combination of follow-up and mass  
166 testing cooperatively suppresses the infectious spread (blue region in the upper panel of Fig. 4A). We also  
167 realize that the maximum number of hospitalisations is immediately saturated by either the follow-up or  
168 mass testing because of the limited hospitalisation capacity (upper panel in Fig. 4B). The maximum number

169 of positive tests increases more efficiently with the follow-up testing rate compared to the mass testing rate  
170 (upper panel in Fig. 4C).

171 Subsequently, realistic scenarios were considered by adapting the limited resource  $L$ . Practically, we  
172 cannot freely control the follow-up and mass testing rates because of the limited clinical resources for both  
173 the follow-up and mass testing. Thus, it is necessary to determine the amount of resources allocated to the  
174 follow-up and mass testing. Here, we consider all the possible decisions subject to the limited resource  $L$  as:

$$L = c_f f + c_m m, \#(3.1),$$

175 where  $c_f$  and  $c_m$  indicate the costs for follow-up and mass testing, respectively;  $f$  and  $m$  are reflected by the  
176 decisions on how much follow-up and mass testing are conducted. Considering different  $L$ ,  $c_f$ , and  $c_m$ , based  
177 on the disease, economic and technological situations of each country, we depicted three lines. We observe  
178 that the worst decisions (i.e., the choice of  $f$  and  $m$ ) drastically varied depending on the situation (lower  
179 panels of Fig. 4).

180 Regarding the high resource and low ratio of the cost of follow-up testing to that of the mass testing  
181 cost, the number of cumulative deaths abruptly increases more than 90% compared to the resource fraction  
182 assigned to mass testing (green line in Fig. 4A). This indicates that the mass testing dominant testing is the  
183 worst strategy for minimising the cumulative deaths. On the contrary, considering low resource and high  
184 ratio of follow-up cost to mass testing cost, the number of cumulative deaths abruptly decreases at the  
185 resource fraction of 20% to 30% (blue line in Fig. 4A) assigned to mass testing. Contrary to the previous  
186 case, this result suggests that follow-up-dominant testing is the worst strategy. Regarding the intermediate  
187 situation between the two cases above, the simulation showed a U-shape with the resource fraction assigned  
188 to mass testing ranging from approximately 10 to 80% (orange line in Fig. 4A). This indicates that both  
189 follow-up and mass-dominant testing are strategies to avoid, whereas the optimal strategy is a combination  
190 of the follow-up and mass testing. The choice of  $f$  and  $m$  also changed in the profiles of maximum  
191 hospitalisations and positive reports (Fig. 4B and C). Taken together, the optimal strategy for each  
192 country/region should be sought with the resources considered.

193 Moreover, we examined how the three variables (i.e., the number of cumulative deaths,  
194 hospitalisations, and positive tests) are affected by the testing characteristics (i.e., sensitivity and specificity).  
195 We conducted sensitivity analyses for  $Se$  and  $Sp$  with values from zero to four with 0.01 increments. We  
196 obtained almost the same heatmaps in the sensitivity-specificity space although the heatmaps were inverted  
197 along the x-axis (Fig. 5). The equations (2.7, 2.8, 2.12, and 2.13) reveal that sensitivity and one-specificity  
198 essentially play the same roles in the follow-up and mass testing. The sensitivity and specificity of the test  
199 are not modifiable, whereas the testing strategy can be arbitrary. If the sensitivity is low, an increase in the  
200 mass testing rate can lead to the same infectious result with high sensitivity. On the contrary, if the specificity  
201 is low, a decrease in the follow-up testing rate can lead to the same infectious result with high specificity.  
202 Therefore, we must manage the optimal testing strategy based on the unmodifiable testing sensitivity and  
203 specificity.

204 We have investigated how the infection is expanded based on the testing strategy. However, this is  
205 the point of view of a perfect observer who knows the exact time course of the latent populations. Practically,

206 we are unable to know all the model variables, such as exposed and infectious populations inside and outside  
207 hospitals; nonetheless, we can merely monitor positive reports by follow-up and mass testing. In this study,  
208 we verify whether these two kinds of positive reports reflect the latent infectious population, which is the  
209 most resource-consuming and challenging social issue. Using regression analysis (see Materials and  
210 Methods), we demonstrate that latent infectious populations can be predicted from daily positive reports of  
211 follow-up and mass testing (Fig. 6A to C). These results suggest that the infectious population is not simply  
212 proportional to the sum of positive reports of follow-up and mass testing; nevertheless, they are proportional  
213 to their weighted sum (Fig. 6D). There are cases in which either weights can be negative, depending on the  
214 model parameters. We found that the weight for positive reports of follow-up testing was negative with high  
215 positive predictive values. This is because the negative weight of  $P_f$  acts in a repressive manner to estimate  
216 the latent number of infectious people, reflecting a low positive predictive value (Fig. 6D).

217

## 218 4. Discussion

219 We develop a testing-SEIRD model to consider two discrete populations inside and outside hospitals, impact  
220 of examination strategy (follow-up testing [ $f$ ], and mass testing [ $m$ ]), and testing characteristics (sensitivity  
221 [ $Se$ ] and specificity [ $Sp$ ]) on three variables (i.e., the number of maximum positive tests, maximum  
222 hospitalisations, and cumulative deaths (Fig. 1)). We also demonstrate that the optimal and worst  
223 examination strategies are subject to limited testing resources (Fig. 4). In addition, we highlight the  
224 possibility that the infectious population can be predicted by a weighted sum of positive reports from follow-  
225 up and mass testing (Fig. 6).

226

### 227 (a) Comparison with previous models.

228 There are several models of infectious dynamics, such as SIR [19], SEIRD models, and their alternatives,  
229 which have been widely used for policy making through model simulation [1,4,20–26]. However, some of  
230 the previous models do not include the hospital compartment, [20,25,27–29] and other models, even with  
231 hospital compartments, do not consider the examination strategy and testing characteristics [22,30]. They  
232 cannot address how the examination strategy and testing characteristics affect infectious population  
233 dynamics, such as clinical and social overshoot. Consequently, we develop the testing-SEIRD model by  
234 introducing new factors: the hospital compartment, examination strategy, and testing characteristics to the  
235 previous SEIRD model (Fig. 2 and 3). The testing-SEIRD model generalises the classical SEIRD model, and  
236 it can be equivalent to the classical SEIRD model if the examination strategy is removed ( $f=0, m=0$ ).

237

### 238 (b) Model prediction

239 This model has three advantages. First, the testing-SEIRD model provides the best examination strategy for  
240 situations. The model provided heatmaps of the number of the three variables in the space of the examination  
241 strategy (Fig. 4). This map indicates the best direction as shown in the blue region in Fig. 4. This corresponds  
242 to the settling of infections using the shortest path. Second, the testing-SEIRD model can predict the optimal  
243 and worst strategies, considering the limited resources and ratios for the testing costs (Fig. 4). Because the  
244 total resource and testing costs depend on countries, our model offers the best examination strategy unique to  
245 each country. Third, the testing-SEIRD model demonstrate that the latent number of infectious population  
246 can be predicted from daily positive reports of the follow-up and mass testing (Fig. 6).

247

### 248 (c) Validity of model components

249 Here, we discuss the validity of the model components, which previous models do not have. First, we focus  
250 on the transition from  $E_o$  to  $E_h$  (Fig. 1). We assume that the hospitalisation of the exposed population is  
251 induced by the follow-up testing. Populations that are just exposed before developing symptoms do not take  
252 the tests themselves. They test only when urged by the follow-up. Second, related to the transition from  $I_o$  to  
253  $I_h$ , we assume that the hospitalisation of the infectious population is induced by the mass testing, which is  
254 defined as a person with symptoms. Considering our model, we address the rate of mass testing as a

255 modifiable parameter because the rate depends on the volume of the tests, such as polymerase chain reaction  
256 (PCR) and the degree of social penalty if it is positive. Third, we consider the transition from  $E_o$  to  $S_o$  and  $E_h$   
257 to  $S_h$ . Regarding our model, all the exposed populations are not necessarily infected and some return  
258 susceptible compared to the previous models which assume that all the exposed populations are destined to  
259 be infected [20,22,24,25,27–33]. Consistent with our model, it is well known that some exposed populations  
260 return to susceptible populations without developing symptoms.

261

#### 262 **(d) Future studies**

263 Considering the future perspectives of our model, first, our testing-SEIRD model simulates only a single  
264 peak time course of infection. However, we observed multiple peaks of COVID-19 infection in many  
265 countries [34]. To incorporate the multiple peaked dynamics, we must introduce the socio-psychological  
266 effects caused by policies such as lockdown and social distancing. Second, our model assumes that all the  
267 populations are homogeneous and do not address stratification based on attributes such as gender, age, social  
268 activities, and comorbidities [35,36]. A future study should consider this perspective. Finally, our model does  
269 not include the effects of vaccination. We are currently fighting the spread of COVID-19 using messenger  
270 RNA (mRNA) vaccines. It seems we are getting successful results; however, we do not know the duration of  
271 the effect of the vaccinations and its robustness against mutants [34,37,38]. Therefore, the tag-of-war model  
272 between vaccines and virus evolution remains elusive.

273

## 274 5. Materials and Methods

### 275 (a) Parameter set

276 The parameters and initial conditions of the simulation are listed in Table 1A. The total population  $N$  was set  
277 to 1,000,000 according to the United Nations Statistical Papers: The World's Cities in 2018, which  
278 mentioned that one in five people worldwide lives in a city with more than one million inhabitants and the  
279 median value of inhabitants is between 500,000 and one million [39]. Sensitivity  $Se$  and specificity  $Sp$  were  
280 both set to 0.7, which correspond to those of the PCR for detecting COVID-19 (Table 1B) [20,31,40–42].  
281 The values of  $b$ ,  $g$ ,  $r_h$ ,  $r_o$ , and  $d_h$  are based on previous reports (Table 1C) [3,21–26,28–30,32]. The sum of  $u$   
282 and  $g$  is the inverse of the incubation period during the exposed state, which is reported to be five days  
283 (Table 1C) [23–25,33,41,43,44]. The sum of  $r$  and  $d$  is the inverse of the infectious period during the  
284 infectious state, which is reported to be ten days (Table 1D) [23,24,27,41,43].

285

### 286 (b) Definitions of reproduction numbers

287 Considering Fig. 2, we computed the time courses of reproduction numbers inside and outside hospitals:  $RN_h$   
288 and  $RN_o$ .

$$RN_h = \frac{1}{r_h + d_h} \cdot \frac{bS_h}{S_h + E_h + I_h} \cdot \frac{g}{u + g}, \#(5.1)$$

$$RN_o = \frac{1}{r_o + d_o} \cdot \frac{bS_o}{S_o + E_o + I_o + R_o + R_h} \cdot \frac{g}{u + g}. \#(5.2)$$

289 Here, the first, second, and third factors in these equations indicate the average infectious period, infection  
290 rate, and probability that the exposed state transits to the infectious state, respectively. The reproduction  
291 number in the classical SEIRD model is defined in previous studies [1,4,20–26] as:

$$RN = \frac{1}{r + d} \cdot \frac{bS}{S + E + I + R}. \#(5.3)$$

292

293

## 294 **Acknowledgments**

295 We thank Tomohiko Takada M.D. (Ph.D.) and Yoshika Onishi M.D. (Ph.D.) for providing the basic concept of  
296 clinical NNT. We also thank Prof. Hiroshi Nishiura for providing the fundamental knowledge of infectious disease  
297 modelling by organising a summer boot camp in 2014.

298

## 299 **Funding**

300 This study was partly supported by the Cooperative Study Program of Exploratory Research Centre on Life and  
301 Living Systems (ExCELLS) (program Nos.18-201, 19-102, and 19-202 to H.N.), a Grant-in-Aid for Young  
302 Scientists (B) (16K16147 and 19H04776 to H.N.) from the Japan Society for the Promotion of Science (JSPS).

303

## 304 **Ethics**

305 Any human or animal subjects are not involved in this manuscript.

306

## 307 **Data Availability**

308 All relevant data are within the study and its supporting information files.

309

## 310 **Code Availability**

311 <https://github.com/bougtoir/testing-SEIRD>

312

## 313 **Author Contributions**

314 O.T. and Y.I. conceived of the initial ideas. O.T. developed and implemented the method, processed, and analysed  
315 the data, and wrote the initial draft of the manuscript. H.N. edited the initial draft of the manuscript and reviewed  
316 the method. Y.I. supervised the project. All authors contributed to the final writing of the manuscript.

317

## 318 **Competing Interests**

319 The authors declare no competing interests.


320

## 321 **References**

- 322 1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. 2020 COVID-19 infection: Origin, transmission, and characteristics  
323 of human coronaviruses. *Journal of Advanced Research* **24**, 91–98. (doi:10.1016/j.jare.2020.03.005)
- 324 2. Kolifarhood G, Aghaali M, Saadati HM, Taherpour N, Rahimi S, Izadi N, Saeed S, Nazari H. 2020 Epidemiological and  
325 Clinical Aspects of COVID-19; a Narrative Review. *Clinical Aspects of COVID* **8**, 41.
- 326 3. Johns Hopkins Coronavirus Resource Center. In press. COVID-19 Map - Johns Hopkins Coronavirus Resource Center. See  
327 <https://coronavirus.jhu.edu/map.html> (accessed on 21 May 2020).
- 328 4. Roguski KM *et al.* 2019 Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *The*  
329 *Lancet* **391**, 1285–1300. (doi:10.1016/S0140-6736(17)33293-2.Estimates)
- 330 5. World health organization. In press. Coronavirus disease 2019 (COVID-19) Situation Report – 46.
- 331 6. Zhou F *et al.* 2020 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a  
332 retrospective cohort study. *The Lancet* **395**, 1054–1062. (doi:10.1016/S0140-6736(20)30566-3)
- 333 7. Giwa AL, Desai A, Duca A. 2020 Novel 2019 coronavirus SARS-CoV-2 (COVID-19): An updated overview for emergency  
334 clinicians. *Emergency medicine practice* **22**, 1–28.
- 335 8. Zhu S, Guo X, Geary K, Zhang D. 2020 Emerging Therapeutic Strategies for COVID-19 Patients. *Discoveries* **8**, e105.  
336 (doi:10.15190/d.2020.2)
- 337 9. Stratton SJ. 2020 COVID-19: Not a Simple Public Health Emergency. *Prehospital and Disaster Medicine* **35**, 119.  
338 (doi:10.1017/S1049023X2000031X)
- 339 10. Swiss Academy Of Medical Sciences. 2020 COVID-19 pandemic: triage for intensive-care treatment under resource scarcity.  
340 *Swiss medical weekly* **150**, w20229. (doi:10.4414/smw.2020.20229)
- 341 11. The Japanese society of intensive care medicine. In press. COVID19 Clinical report 20200322 v3.
- 342 12. ANZICS. In press. ANZICS COVID-19 Guidelines Version 2 - ANZICS. See [https://www.anzics.com.au/anzics-covid-19-](https://www.anzics.com.au/anzics-covid-19-guidelines-version-2/)  
343 [guidelines-version-2/](https://www.anzics.com.au/anzics-covid-19-guidelines-version-2/) (accessed on 21 May 2020).
- 344 13. Our world in Data. In press. GitHub - owid/covid-19-data: Data on COVID-19 (coronavirus) cases, deaths, hospitalizations,  
345 tests • All countries • Updated daily by Our World in Data. See <https://github.com/owid/covid-19-data> (accessed on 21 May  
346 2020).
- 347 14. World health organization. In press. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 16  
348 March 2020. See [https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020)  
349 [media-briefing-on-covid-19---16-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020) (accessed on 21 May 2020).
- 350 15. Godlee F. 2020 The burning building. *The BMJ* **368**, 2020. (doi:10.1136/bmj.m1101)
- 351 16. Peto J. 2020 Covid-19 mass testing facilities could end the epidemic rapidly. *The BMJ* **368**, 110110.  
352 (doi:10.1136/bmj.m1163)
- 353 17. Japanese society of pediatrics. In press. Thought on COVID-19 testing. See  
354 [http://www.jpeds.or.jp/modules/activity/index.php?content\\_id=329](http://www.jpeds.or.jp/modules/activity/index.php?content_id=329) (accessed on 21 May 2020).
- 355 18. Joebges S, Biller-Andorno N. 2020 Ethics guidelines on COVID-19 triage - An emerging international consensus. *Critical*  
356 *Care* **24**, 1–5. (doi:10.1186/s13054-020-02927-1)
- 357 19. Phelan. 2018 Mathematical models to characterize early epidemic growth: A Review Gerardo. *Physiology & behavior* **176**,

- 358 139–148. (doi:10.1016/j.pprev.2016.07.005.Mathematical)
- 359 20. Fang Y, Nie Y, Penny M. 2020 Transmission dynamics of the COVID-19 outbreak and effectiveness of government  
360 interventions: A data-driven analysis. *Journal of medical virology* (doi:10.1002/jmv.25750)
- 361 21. Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. 2020 An updated estimation of the risk of transmission of the novel  
362 coronavirus (2019-nCov). *Infectious Disease Modelling* **5**, 248–255. (doi:10.1016/j.idm.2020.02.001)
- 363 22. Kucharski AJ *et al.* 2020 Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *The  
364 Lancet Infectious Diseases* **20**, 553–558. (doi:10.1016/S1473-3099(20)30144-4)
- 365 23. Backer J, Klinkenberg D, Wallinga J. 2020 The incubation period of 2019-nCoV infections among travellers from Wuhan,  
366 China. *Eurosurveillance* , 1–6. (doi:10.1101/2020.01.27.20018986)
- 367 24. Bi Q *et al.* 2020 Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen,  
368 China: a retrospective cohort study. *The Lancet Infectious Diseases* **20**, 911–919. (doi:10.1016/S1473-3099(20)30287-5)
- 369 25. Kuniya T. 2020 Prediction of the Epidemic Peak of Coronavirus Disease in Japan, 2020. *Journal of clinical medicine* **9**.  
370 (doi:10.3390/jcm9030789)
- 371 26. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R, Nishiura H. 2020  
372 Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: A  
373 statistical analysis of publicly available case data. *Journal of Clinical Medicine* **9**, 538. (doi:10.1101/2020.01.26.20018754)
- 374 27. Joseph TW, Leung K, Leung GM. 2020 Nowcasting and forecasting the potential domestic and international spread of the  
375 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* , 689–697.
- 376 28. Iwata K, Miyakoshi C. 2020 A Simulation on Potential Secondary Spread of Novel Coronavirus in an Exported Country  
377 Using a Stochastic Epidemic SEIR Model. *Journal of Clinical Medicine* **9**, 944. (doi:10.3390/jcm9040944)
- 378 29. Sun H, Qiu Y, Yan H, Huang Y, Zhu Y, Gu J, Chen S. 2021 Tracking Reproductivity of COVID-19 Epidemic in China with  
379 Varying Coefficient SIR Model. *Journal of Data Science* **18**, 455–472. (doi:10.6339/jds.202007\_18(3).0010)
- 380 30. Rocklöv J, Sjödin H, Wilder-Smith A. 2021 COVID-19 outbreak on the diamond princess cruise ship: Estimating the  
381 epidemic potential and effectiveness of public health countermeasures. *Journal of Travel Medicine* **27**, 1–7.  
382 (doi:10.1093/JTM/TAAA030)
- 383 31. Lin L *et al.* 2020 Artificial Intelligence Distinguishes COVID-19 from Community Acquired Pneumonia on Chest CT.  
384 *Applied Intelligence* **2019**, 1–5.
- 385 32. Roda WC, Varughese MB, Han D, Li MY. 2020 Why is it difficult to accurately predict the COVID-19 epidemic? *Infectious  
386 Disease Modelling* **5**, 271–281. (doi:10.1016/j.idm.2020.03.001)
- 387 33. World health organization. In press. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19).  
388 See [https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-\(covid-19\)](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))  
389 (accessed on 21 May 2020).
- 390 34. GISAID. In press. GISAID - Initiative. See <https://www.gisaid.org/> (accessed on 9 May 2021).
- 391 35. Thomas DM, Sturdivant R, Dhurandhar N v., Debroy S, Clark N. 2020 A Primer on COVID-19 Mathematical Models.  
392 *Obesity* **28**, 1375–1377. (doi:10.1002/oby.22881)
- 393 36. Shahid Z *et al.* 2020 COVID-19 and Older Adults: What We Know. *Journal of the American Geriatrics Society* **68**, 926–929.  
394 (doi:10.1111/jgs.16472)
- 395 37. Sharp TM *et al.* 2021 Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

- 396 *New England Journal of Medicine* **384**, 2257–2259. (doi:10.1056/nejmc2023298)
- 397 38. Christian HH, Daniela M, Sophie MG, Kåre M, Steen E. 2020 Assessment of protection against reinfection with SARS-  
398 CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. *The Lancet* ,  
399 19–21.
- 400 39. United Nations. 2018 The World’s Cities in 2018: Data Booklet. (doi:10.18356/C93F4DC6-EN)
- 401 40. Tao A, Zhenlu Y, Hongyan H, Chenao Z, Chong C, Wenzhi L, Qian T, Ziyong S, Liming X. 2014 Correlation of Chest CT  
402 and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology* **80**, 1–8.  
403 (doi:10.14358/PERS.80.2.000)
- 404 41. Long C *et al.* 2020 Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? *European Journal of Radiology*
- 405 42. Lai S *et al.* 2021 Effect of non-pharmaceutical interventions to contain COVID-19 in China. *Nature* **585**, 410–413.  
406 (doi:10.1038/s41586-020-2293-x.Effect)
- 407 43. Fang J, Lau CKM, Lu Z, Wu W, Zhu L. 2019 Natural disasters, climate change, and their impact on inclusive wealth in G20  
408 countries. *Environmental Science and Pollution Research* **26**, 1455–1463. (doi:10.1007/s11356-018-3634-2)44.
- 409 Ahmad N, Derrible S, Managi S. 2018 A network-based frequency analysis of Inclusive Wealth to track sustainable  
410 development in world countries. *Journal of Environmental Management* **218**, 348–354.  
411 (doi:10.1016/j.jenvman.2018.04.070)
- 412




413

414 **Figure 1: Classical SEIRD and testing-SEIRD models**

415 (A) Classical SEIRD model: Susceptible population 'S' is exposed by infectious population 'I' at a rate  
 416 proportional to the fraction of the infectious population. The exposed population 'E' become infectious 'I'. The  
 417 infected population finally recovers 'R' or become dead 'D'. (B) Testing-SEIRD model: The population is  
 418 divided into two subpopulations; inside and outside hospitals. The exposed 'E<sub>o</sub>' and infectious population  
 419 outside 'I<sub>o</sub>' are hospitalised if evaluated as positive by testing. Susceptible population 'S<sub>h</sub>' is left from the  
 420 hospitals. The black lines indicate the transitions of populations, regardless of capacity effect. The blue lines  
 421 indicate the transitions of the populations, considering the capacity effect. Transitions from both 'E<sub>o</sub>' to 'E<sub>h</sub>'  
 422 and 'I<sub>o</sub>' to 'I<sub>h</sub>' are determined as hospitalised.

423



424

425 **Figure 2: Changes in components over time in the testing-SEIRD model**

426 Time-courses of (A) populations of all infectious states, irrespective of being inside and outside hospitals; (B)


427 Populations inside and outside hospitals and dead populations, irrespective of infectious states; (C)

428 Populations of all infectious states inside hospitals; (D) Populations of all infectious states outside hospitals;

429 (E) Daily reports of positive tests, hospitalisations, and deaths; (F) Time-courses of reproduction numbers

430 inside and outside hospitals, as described in Materials and Methods section.


431



432  
433  
434  
435  
436  
437  
438  
439

**Figure 3: Impact of hospitalisations capacity on the three variables**

Time courses of (A) Daily reports of positive tests; (B) Daily reports of hospitalisations; (C) Daily reports of deaths with varying hospitalisation capacity. C/N indicates the capacity normalised to the total population. Hospitalisation capacity dependencies of (D) Maximum positive reports; (E) Maximum hospitalisations; (F) Cumulative deaths. Hospitalisation capacity-dependencies of (G) Peaks of daily reports of positive tests; (H) Peaks of hospitalisations; (I) Peaks of daily deaths.



440

441

**Figure 4: Infectious spread based on the examination strategy**

442

The upper panels represent the number of (A) cumulative deaths, (B) maximum hospitalisations, and (C)

443

maximum daily positive tests depending on the rates of follow-up and mass testing. The three lines in these

444

heatmaps represent the possible testing strategies subject to different total resources for testing with


445

different ratios for the testing costs. The lower panels represent the numbers along the three lines in the

446

heatmap.

447




448

449 **Figure 5: Infectious spread based on the testing properties**

450 Number of (A) Cumulative deaths, (B) Maximum hospitalisations, and (C) Maximum daily positive tests

451 based on the sensitivity and specificity of the testing.



452

453

**Figure 6: Prediction of infectious population from daily reports of positive tests**

454

(A-C) The Green and orange lines indicate the simulated and predicted infectious populations ( $I_n$  and  $I_o$ ) with different examination strategies. The infectious populations are estimated by the linear regression as  $w_f P_f + w_m P_m$ , where  $w_f$  and  $w_m$  indicate the weights and  $P_f$  and  $P_m$  indicate the daily positive reports of follow-up and mass testing, namely  $f(1-Sp)$  and  $mSe$ , respectively. The weights are estimated by the least square method.

457

458

(D) The estimated weights for  $P_f$  and  $P_m$  are plotted, considering various combinations of ratios of the follow-up cost to the mass testing cost ( $P_f/P_m$ ).

459

460

A		C								
Variable	Value	Reference	Model	$b$	$g$	$r_h$	$r_o$	$d_h$	$d_o$	
$S_h, E_h, I_h$	1	Fang <sup>20</sup>	eSEIR	0.9 e-5 to e-6†	0.143	0.056	n/a	n/a	n/a	
$I_o$	97	Tang <sup>21</sup>	n/a	2.1 e-8	0.126	n/a	0.14	1.78 e-5	n/a	
$S_o$	999900	Kucharski <sup>22</sup>	eSEIR	n/a	0.156	n/a	n/a	n/a	n/a	
$E_o, R_h, R_o, D_h, D_o$	0	Backer <sup>23</sup>	n/a	n/a	0.143 to 0.33	n/a	n/a	n/a	n/a	
		Bi Q <sup>24</sup>	n/a	n/a	n/a	n/a	n/a	n/a	n/a	
		Kuniya <sup>25</sup>	SEIR	0.2 e-8†	n/a	n/a	n/a	n/a	n/a	
		Linton <sup>26</sup>	n/a	n/a	0.2	n/a	n/a	n/a	n/a	
		Iwata <sup>28</sup>	SEIR	n/a	0.167 to 0.208	0.13 to 0.417	n/a	n/a	n/a	
		Sun, H <sup>29</sup>	vSIR	n/a	n/a	0.1	n/a	n/a	n/a	
		Rocklöv <sup>30</sup>	SEIR	0.4 e-4 or 0.12 e-4†	0.2	n/a	n/a	n/a	n/a	
		Roda <sup>32</sup>	SIR/SEIR	8.68 e-8	0.631	0.1	n/a	n/a	n/a	

B		C		D		
Mode of test	Se	Sp	Reference	Incubation period	Infectious period	
CT	0.98 <sup>20</sup> , 0.97 <sup>31,40</sup>	0.828 to 0.96 <sup>41</sup>	Kucharski <sup>22</sup>	5.2	2.9	
	0.8 to 0.9 <sup>41</sup> , 0.972 <sup>42</sup>		Backer <sup>23</sup>	6.5	n/a	
PCR	0.71 <sup>20</sup> , 0.846 <sup>42</sup>	n/a	Bi <sup>24</sup>	4.8	1.5	
			Wu <sup>27</sup>	6.1	2.3	
			Rocklöv <sup>30</sup>	5	10	
			Li <sup>31</sup>	5.2	2.3	
			WHO-China Joint <sup>33</sup>	5.5	n/a	

461

462


**Table 1: Variables and parameters in previous reports**

463

(A) Initial values for variables and parameters and (B) Reported sensitivity and specificity of PCR and CT for detecting COVID-19. Cells expressed as n/a indicate that we cannot find the (C) reported transition parameters with models. Values with † are calculated from the original values for comparison. All the values have dimensions of [one/day]. We cannot find values or models for the cells expressed as n/a. The values with † equal original values divided by the total population involved. (D) Reported incubation period and infectious period. All values have dimensions of [day].

469

470 **Supplementary Figures**




471

472 **Figure S1: Sensitivity analyses of parameters  $b$  and  $m$  on the number of cumulative deaths**

473 Simulations were performed with different values of  $b$  and  $m$ .

474



475

476

**Figure S2: Sensitivity analyses of parameter  $a$  on the number of cumulative deaths**

477

Simulations were performed with different values of  $a$ .

478